drugset
drugset / Trial / NCT04755075

Surufatinib Hepatic Impairment Study

NCT04755075 ↗

Phase 1 Completed 16 enrolled Hutchison Medipharma Limited
Non-randomizedParallel-groupOpen-labelOther

Summary

An open-label, multicenter, single-dose, single-period, sequential study to determine the effect of hepatic impairment on the PK of surufatinib.

Timeline

Start
2021-02-12
Primary completion
2021-10-11
Completion
2021-10-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Surufatinib Small molecule 250 mg —

Indications

No indication recorded.